Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
Top Page
Eton Pharmaceuticals
(NASDAQ:ETON)
Select Model
Select Model
Rating:66Neutral
Price Target:
$24.00
▲(2.35% Upside)
Action:ReiteratedDate:03/21/26
The score is driven primarily by improving financial performance and a constructive earnings outlook (strong 2026 guidance with expanding margins), supported by bullish price trend signals. Offsetting factors are an overheated momentum setup (RSI/Stoch elevated) and weak valuation support given the negative P/E and no dividend yield.
Positive Factors
Accelerating revenue growth
Rapid, sustained top-line expansion reflects successful commercial execution and multiple product launches. Doubling 2025 revenue plus guidance >$110M for 2026 indicates expanding market penetration and recurring product sales that can support scale in sales, access programs, and future R&D investment.
Negative Factors
GAAP profitability still negative
Despite adjusted metrics improving, GAAP losses and negative ROE indicate the business has not fully converted operational gains into reported profitability. Persistent GAAP losses constrain retained earnings, may limit capital return options, and leave reliance on continued margin expansion and revenue execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating revenue growth
Rapid, sustained top-line expansion reflects successful commercial execution and multiple product launches. Doubling 2025 revenue plus guidance >$110M for 2026 indicates expanding market penetration and recurring product sales that can support scale in sales, access programs, and future R&D investment.
Read all positive factors
Eton Pharmaceuticals (ETON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$639.82M
Dividend YieldN/A
Average Volume (3M)378.62K
Price to Earnings (P/E)76.7
Beta (1Y)0.94
Revenue Growth102.77%
EPS Growth-17.00%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.05
Shares Outstanding27,284,490
10 Day Avg. Volume521,537
30 Day Avg. Volume378,621
Financial Highlights & Ratios
PEG Ratio-7.42
Price to Book (P/B)17.40
Price to Sales (P/S)5.69
P/FCF Ratio44.65
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.79
Enterprise Value/Gross Profit14.58
Enterprise Value/Ebitda162.82
Forecast
1Y Price Target
$39.33Price Target Upside67.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.02
Revenue Forecast (FY)$105.27M
Eton Pharmaceuticals Business Overview & Revenue Model
Company Description
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important h...
How the Company Makes Money
Eton Pharmaceuticals primarily makes money by selling FDA-approved prescription drugs. Revenue is generated from product sales to pharmaceutical wholesalers, specialty pharmacies, hospitals, and other healthcare channels that purchase Eton’s brand...
Eton Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call communicated a strong operational and financial momentum: substantial revenue growth (Q4 +83% YoY), material margin improvement (adjusted EBITDA margin up to 29%), multiple successful launches (Desmota, Galzin relaunch) and an accretive cash acquisition (Hemangiol). Management provided ambitious but concrete 2026 guidance (> $110M revenue, ≥30% adjusted EBITDA margin) and laid out multi-year targets that tie commercial execution to margin expansion. Near-term headwinds include Q4 cash outflow driven by large Medicaid rebates and newly triggered FDA program fees, some margin volatility from ex-U.S. Incralex orders, and execution/timing risks around label expansions and clinical studies. Overall, the positives—rapid revenue scaling, improving profitability, multiple product launch catalysts, and a strengthened pipeline—appear to significantly outweigh the manageable near-term financial and execution risks.Positive Updates
Strong Revenue Growth
Q4 product revenue of $21.3M, up 83% year-over-year (Q4 2024: $11.6M); company more than doubled revenue in 2025 versus 2024 and provided 2026 guidance of revenue expected to exceed $110M.
Negative Updates
Near-Term Cash and Cash Flow Pressure
Company ended Q4 with $25.9M cash on hand and reported an operating cash outflow of $11.6M in 2025 (vs. operating cash inflow of $12.0M in the previous quarter). Q4 included $12.4M of Medicaid rebate payments and $3.5M of FDA program fees, creating near-term liquidity pressure.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Q4 product revenue of $21.3M, up 83% year-over-year (Q4 2024: $11.6M); company more than doubled revenue in 2025 versus 2024 and provided 2026 guidance of revenue expected to exceed $110M.
Read all positive updates
Company Guidance
Management guided 2026 revenue to exceed $110 million with an adjusted EBITDA margin of at least 30% (after 2025 adjusted EBITDA of $6.2M, ~29% of revenue) and expects adjusted gross margin comfortably above 70% in 2026, ramping to 75–80% in the coming years; they also targets a $200M revenue run rate exiting 2027, a 50% adjusted EBITDA margin in 2028, $500M revenue by 2030, and growing the commercial portfolio to 13–14 products (currently 10). Product-level assumptions include Desmota peak sales potential of $30–$50M (management estimates ~ $80,000 net revenue per patient per year and an addressable population of ~3–4k pediatric plus ~9–10k adults), an Alkindi/Candivy franchise peak of at least $50M (targeting ~20% of an estimated 5k pediatric market), ET700 peak >$100M, Incrolex could expand ~5× with label harmonization, and Hemangiol (acquired for $14M) treats ~5–10k infants annually and could be a top product in 2027. Additional financials: year-end cash $25.9M, 2025 operating cash outflow $11.6M but expected positive operating cash flow in 2026, 2026 R&D likely < $10M, and 2026 SG&A to rise due to FDA program fees (~$442k/strength ×8 = $3.5M, ~$2.8M incremental) plus Hemangiol (~$3.5M annualized, ~$2.5M partial‑year).Eton Pharmaceuticals Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 79.95M | 39.01M | 31.64M | 21.25M | 21.83M |
| Gross Profit | 42.74M | 23.41M | 21.06M | 14.32M | 19.21M |
| EBITDA | 4.12M | -1.45M | -291.00K | -6.49M | -1.03M |
| Net Income | -4.60M | -3.82M | -936.00K | -9.02M | -1.96M |
Balance Sheet | |||||
| Total Assets | 92.11M | 76.12M | 31.74M | 25.03M | 27.46M |
| Cash, Cash Equivalents and Short-Term Investments | 25.94M | 14.94M | 21.39M | 16.30M | 14.41M |
| Total Debt | 9.25M | 29.92M | 5.40M | 6.52M | 6.70M |
| Total Liabilities | 65.96M | 51.70M | 16.26M | 11.95M | 9.84M |
| Stockholders Equity | 26.15M | 24.43M | 15.48M | 13.08M | 17.63M |
Cash Flow | |||||
| Free Cash Flow | 10.19M | 943.00K | 6.04M | 2.03M | -7.98M |
| Operating Cash Flow | 10.52M | 969.00K | 6.82M | 4.82M | -4.72M |
| Investing Cash Flow | -333.00K | -40.01M | -775.00K | -2.79M | -2.56M |
| Financing Cash Flow | 815.00K | 32.59M | -957.00K | -134.00K | 391.00K |
Eton Pharmaceuticals Technical Analysis
Positive
23.45
Price Trends
17.34
Positive
17.01
Positive
16.91
Positive
Market Momentum
1.71
Negative
74.28
Negative
85.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ETON, the sentiment is Positive. The current price of 23.45 is above the 20-day moving average (MA) of 19.42, above the 50-day MA of 17.34, and above the 200-day MA of 16.91, indicating a bullish trend. The MACD of 1.71 indicates Negative momentum. The RSI at 74.28 is Negative, neither overbought nor oversold. The STOCH value of 85.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ETON.
Eton Pharmaceuticals Risk Analysis
Eton Pharmaceuticals disclosed 45 risk factors in its most recent earnings report. Eton Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eton Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $639.82M | 76.71 | -18.84% | ― | 102.77% | -17.00% | |
56 Neutral | $440.70M | -4.14 | -59.68% | ― | -33.09% | 3.38% | |
54 Neutral | $577.57M | -5.15 | -26.87% | ― | ― | 60.40% | |
54 Neutral | $1.34B | -13.24 | -28.72% | ― | ― | -44.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $426.32M | -2.77 | -103.12% | ― | 91.30% | 30.69% |
* Healthcare Sector Average
ETON
Eton Pharmaceuticals
23.45
9.94
73.58%
RGNX
RegenXBio
8.26
0.35
4.42%
TECX
Tectonic Therapeutic
30.76
11.85
62.67%
ABSI
AbSci
2.88
0.07
2.49%
MBX
MBX Biosciences, Inc.
28.29
20.88
281.78%
Eton Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
Positive
Mar 2, 2026
On February 27, 2026, Eton Pharmaceuticals entered a licensing agreement to acquire the U.S. rights to HEMANGEOL, the only FDA-approved propranolol oral solution for infantile hemangioma requiring systemic therapy, from Pierre Fabre Medicament. Th...
Business Operations and StrategyProduct-Related Announcements
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy
Positive
Feb 25, 2026
On February 25, 2026, Eton Pharmaceuticals announced U.S. FDA approval of DESMODA, the first and only FDA-approved desmopressin oral solution, for management of central diabetes insipidus as antidiuretic replacement therapy in adults and children....
Business Operations and StrategyProduct-Related Announcements
Eton Pharmaceuticals Licenses U.S. Rights to Ultra-Rare Drug
Positive
Feb 2, 2026
On February 2, 2026, Eton Pharmaceuticals announced it had licensed U.S. marketing rights to an ultra-rare disease product candidate that, once approved, is expected to become the first and only generic alternative to a treatment for a condition a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.